| Literature DB >> 34833885 |
Teruki Nii1,2.
Abstract
Gelatin, a denatured form of collagen, is an attractive biomaterial for biotechnology. In particular, gelatin particles have been noted due to their attractive properties as drug carriers. The drug release from gelatin particles can be easily controlled by the crosslinking degree of gelatin molecule, responding to the purpose of the research. The gelatin particles capable of drug release are effective in wound healing, drug screening models. For example, a sustained release of growth factors for tissue regeneration at the injured sites can heal a wound. In the case of the drug screening model, a tissue-like model composed of cells with high activity by the sustained release of drug or growth factor provides reliable results of drug effects. Gelatin particles are effective in drug delivery and the culture of spheroids or cell sheets because the particles prevent hypoxia-derived cell death. This review introduces recent research on gelatin microparticles-based strategies for regenerative therapy and drug screening models.Entities:
Keywords: biotechnology; drug delivery; drug research model; gelatin; regenerative medicine
Mesh:
Substances:
Year: 2021 PMID: 34833885 PMCID: PMC8617939 DOI: 10.3390/molecules26226795
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Comparison of features between chemical and dehydrothermal crosslinking methods.
| Points Compared | Crosslinking Method | |
|---|---|---|
| Chemical | Dehydrothermal | |
| Instrument needed | Nothing | Oven |
| Temperature (°C) | 40 | 140~160 |
| Particle condition under process | Liquid | solid |
| Crosslinking reagent added | Aldehyde, isocyanates, acyl azides, or carbodiimide [ | Nothing |
| Stop reagent added | Glycine [ | Nothing |
| Time required (days) | 1 | 2~5 |
| Merit |
Safety condition (room temperature condition) [ Particular instrument is not needed [ |
Easy to handle [ Aggregation is not formed because of the solid condition. |
| Demerit |
Aggregation is sometimes formed. |
Particular instrument is needed [ |
Figure 1A schematic representation of drug release from gelatin particles (when the isoelectric point of gelatin is negative.). The gelatin used for sustained drug release can be selected considering the isoelectric point of the drug (If the drug to be released is basic, gelatin with a negative charge is preferable.). Drugs and gelatin molecules interact by physicochemical interaction (e.g., ionic or hydrogen interaction). When the gelatin particles are degraded, the drugs with gelatin molecule debris are rapidly released with time.
Examples of regenerative therapy and tissue regeneration strategies using gelatin microparticles.
| Ref. | Date | Tissue | In Vitro (Cell Type)/In Vivo | Growth Factors Released | Main Results |
|---|---|---|---|---|---|
| [ | 2015 | Cardiac | In vitro (human cardiac cells derived from iPS cells)/In vivo (mouse) | - | The survival rate of stacked cell sheets was improved by incorporating gelatin microparticles between each cell sheet. |
| [ | 2017 | Blood vessels | In vitro (human umbilical vein endothelial cells and human dermal fibroblast cells)/In vivo (mouse) | Platelet-rich plasm | Gelatin microparticles containing PRP promoted the formation of capillaries and microvascular networks. |
| [ | 2018 | Sternal | In vivo (rabbit) | PRP | PRP-gelatin microparticles injection showed a significantly higher indicator of sternal healing than only gelatin microparticles injection. |
| [ | 2018 | Bone | In vitro (mouse mesenchymal stem cells and mouse macrophages) | Bone morphogenic protein-2 | The gelatin microparticles were prepared to be preferentially degraded by pro-inflammatory macrophages, leading to the spatiotemporal BMP-2 release. The strategy enabled to achieve the efficient bone differentiation of stem cells. |
| [ | 2018 | Cardiac | In vivo (rat) | Basic fibroblast growth factor | Gelatin microparticles capable of bFGF control release showed the improvement of cell sheets’ viability. |
| [ | 2019 | Cartilage | In vitro (human | Transforming growth factor-β1 | TGF-β1 release from gelatin microparticles promotes the chondrogenic differentiation of human periosteum-derived cells. |
| [ | 2019 | Bone | In vitro (rabbit | BMP-2 | BMP-2 release system of gelatin microparticles is effective in bone regeneration of X-ray-radius defects. |
| [ | 2021 | Cartilage and disk | In vitro (human stem cells)/In vivo (rat) | Matrilin3 and TGF-β3 | Chondrogenic differentiation was promoted when gelatin particles containing Matrilin-3 and TGF-β3 were incorporated into stem cell spheroids while preventing hypertrophy. |
| [ | 2021 | Masseter muscle | In vitro | bFGF and PRP | The combination of cell transplantation and the drug release system efficiently differentiated stem cells towards muscle lineage. |
In vitro drug research studies using 3D cell/tissue spheroids combined with gelatin microparticles.
| Ref. | Date | Tissue or Disease | Cells Used | Growth Factors or Drugs Released | Main Results |
|---|---|---|---|---|---|
| [ | 2017 | Epithelial | Mammary epithelial cells | - | β-casein expression of epithelial spheroids incorporating gelatin microparticles coated with Matrigel was higher than microparticles-free spheroids. |
| [ | 2017 | Cancer | Cancer-associated fibroblasts and cancer cells | - | Cancer cells and cancer-associated fibroblasts (CAF) spheroids combined with gelatin particles showed a stromal matrix rich in collagen deposition and expressed the desmoplastic reaction markers. |
| [ | 2017 | Epithelial | Mammary epithelial cells and preadipocyte cells | - | Epithelial-preadipocytes multicellular spheroids incorporating gelatin microparticles showed the enhancement of β-casein expression compared to spheroids in the absence of the gelatin microparticles. |
| [ | 2017 | Bone | Pre-osteoblast cells | Bone morphogenic proteins-2 (BMP-2) | When spheroids incorporating gelatin microparticles containing BMP-2 were prepared, efficient osteogenic differentiation was observed compared to spheroids incorporating gelatin microparticles. |
| [ | 2018 | Cancer | Cancer-associated fibroblasts and cancer cells | - | Cancer cells and CAF spheroids embedded gelatin particles enabled the evaluation of the anti-cancer drug effects efficiently. |
| [ | 2018 | Pancreas | Insulinoma cells | - | The insulinoma spheroids incorporating gelatin microparticles prompted the secretion of insulin. |
| [ | 2018 | Cancer | Cancer cells, endothelial cells, and fibroblasts | - | 3D tissue model consisting of cancer cells, endothelial cells, and fibroblasts was prepared. In this model, aberrant capillary-like structures were observed, which are important events of breast cancer progression. |
| [ | 2019 | Cancer | Cancer-associated fibroblasts and cancer cells | p53 inhibitor | CAF spheroids incorporating gelatin microparticles containing a p53 inhibitor were prepared to activate the CAF function in vitro, similar to in vivo. The activated CAF spheroids can promote the invasion ability of cancer cells. |
| [ | 2020 | Cancer | Cancer-associated fibroblasts and cancer cells | Transforming growth factor-β | CAF spheroids incorporating gelatin microparticles containing TGF-β enabled increased invasion rate of cancer cells, responding to TGF-β concentration. |
| [ | 2020 | Cancer | Cancer-associated fibroblasts, macrophages, and cancer cells | Adenosine and TGF-β | 3D tumor-associated macrophages incorporating gelatin microparticles containing adenosine and 3D CAF incorporating gelatin microparticles containing TGF-β were combined. This system can mimic the tumor microenvironment, responding to the tissue region. |